Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-20
2007-02-20
Tsang, Cecilla J. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S216000
Reexamination Certificate
active
10861957
ABSTRACT:
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;wherein X, Y, Z, D and R3are as defined in the specification.Also disclosed are compounds comprisingor a pharmaceutically acceptable salt or a prodrug thereof;wherein A, X, J, and R3are as defined in the specification.Also disclosed are compounds having an α and an ω chain comprisingor derivatives thereof,as defined in the specificationor pharmaceutically acceptable salts or prodrugs thereof.
REFERENCES:
patent: 3975399 (1976-08-01), DeFranco et al.
patent: 4113873 (1978-09-01), Himizu et al.
patent: 4115401 (1978-09-01), Nanthavong et al.
patent: 4119727 (1978-10-01), Buendia et al.
patent: 4177346 (1979-12-01), Nelson
patent: 4299970 (1981-11-01), Cassidy et al.
patent: 4320136 (1982-03-01), Scribner
patent: 4994274 (1991-02-01), Chan et al.
patent: 5028624 (1991-07-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5385945 (1995-01-01), Garst et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 6034093 (2000-03-01), Ewing et al.
patent: 6258844 (2001-07-01), Garst et al.
patent: 6291522 (2001-09-01), Burk
patent: 6303658 (2001-10-01), Burk
patent: 6307092 (2001-10-01), Burk et al.
patent: 6310087 (2001-10-01), Burk
patent: 6359181 (2002-03-01), Burk et al.
patent: 6376533 (2002-04-01), Burk et al.
patent: 6380250 (2002-04-01), Burk
patent: 6380251 (2002-04-01), Burk
patent: 6395787 (2002-05-01), Woodward et al.
patent: 6403649 (2002-06-01), Woodward et al.
patent: 6410591 (2002-06-01), Burk et al.
patent: 6414022 (2002-07-01), Burk
patent: 6476064 (2002-11-01), Old et al.
patent: 6531504 (2003-03-01), Burk et al.
patent: 6538018 (2003-03-01), Burk et al.
patent: 6573294 (2003-06-01), Old et al.
patent: 6586462 (2003-07-01), Burk et al.
patent: 6602900 (2003-08-01), Burk
patent: 6670485 (2003-12-01), Burk et al.
patent: 6680337 (2004-01-01), Burk
patent: 2004/0142969 (2004-07-01), Elworthy
patent: 841165 (1976-10-01), None
patent: 1553595 (1979-10-01), None
patent: 1569982 (1980-06-01), None
patent: 1583163 (1981-01-01), None
patent: 5086034 (1993-04-01), None
patent: WO 89/09800 (1989-10-01), None
patent: WO 89/11275 (1989-11-01), None
patent: WO 93/03825 (1993-03-01), None
patent: WO 96/41639 (1996-12-01), None
patent: WO 00/21532 (2000-04-01), None
patent: WO 00/21542 (2000-04-01), None
patent: WO 01/46140 (2001-06-01), None
patent: WO2004/085430 (2004-07-01), None
Bito, L.Z.,Biological Protection with Prostaglandins,Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252.
Bito, L.Z.,Applied Pharmacology in the Medical Treatment of Glaucomas,Drance, S.M. and Neufeld, A.H. eds, New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson et al, Invest.Ophthalmol. Vis. Sci.(suppl), 284 (1987).
Bito, L.Z.,Arch. Ophthalmol.105, 1036 (1987).
Siebold et al,Prodrug5 3 1989.
Huang et al, Synth. Commun., “Preparation of Optically Pure ω-Hydroxymethyl Lactams”, 1989, 19, 3485-3496.
Ono, K., et al., “Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2” J. Endocrinology (1998) 158, R1-R5.
Saijo, S., et al., Heterocyclic prostaglandins IV “Synthesis of 8-Aza-11-deoxyprostaglandin E1and its related compounds”, Yakugaku Zasshi 100 (4) 389-395 (1980).
Suda, M., et al., “Prostaglandin E ReceptorSubtypes in mouse osteoblastic cell line”, Endocrinology 1996, vol. 137, No. 5, pp. 1698-1705.
Suzawa, T., et al., “The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for the respective EPs”, Endocrinology, 2000, vol. 141, No. 4, pp. 1554-1557.
Zoretic, P.A., et al., “Synthesis of (E)-7-[[2-[4-(m-trifluoromethylphenoxy)-3α and 3β-hydroxy-1-butenyl]-5-oxo-1-pyrrolidinyl]]heptanoic acids” J. Heterocyclic Chem., 20, 465, (1983).
Dinh Danny T.
Old David W.
Allergan Inc.
Baran Robert J.
Covington Raymond
Johnson Brent A.
Tsang Cecilla J.
LandOfFree
Piperidinyl prostaglandin E analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidinyl prostaglandin E analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinyl prostaglandin E analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3869439